Jacobs & Co. CA Has $6.55 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Jacobs & Co. CA increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 9,191 shares of the biopharmaceutical company’s stock after purchasing an additional 64 shares during the period. Jacobs & Co. CA’s holdings in Regeneron Pharmaceuticals were worth $6,547,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $37,000. Ashton Thomas Private Wealth LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $39,000. Finally, Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Finally, Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $1,037.33.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $38.89 during mid-day trading on Friday, reaching $694.70. 700,147 shares of the company’s stock were exchanged, compared to its average volume of 682,965. The business’s fifty day simple moving average is $754.37 and its 200 day simple moving average is $965.13. The firm has a market capitalization of $76.34 billion, a PE ratio of 17.19, a P/E/G ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a one year low of $691.00 and a one year high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.